Suspension of trading

ETFs Forte Biosciences

FBRX

US34962G2084

Market Closed - Nasdaq 16:00:00 2026-08-26 EDT			5-day change	1st Jan Change
76.99 ^USD	+0.03%		-.--%	+182.32%

08-30	Forte Biosciences, Inc.(NasdaqGM:FBRX) dropped from Russell 3000E Growth Index	CI
08-30	Forte Biosciences, Inc.(NasdaqGM:FBRX) dropped from Russell Microcap Growth Index	CI

ETFs positioned on Forte Biosciences

Name	YTD change	Weight	AuM
ISHARES MICRO-CAP ETF - USD	+19.92%	0.06%	1,518 M€
AVANTIS U.S. SMALL CAP EQUITY ETF - USD	+19.83%	0.01%	3,154 M€
VANGUARD MORNINGSTAR TOTAL STOCK MARKET ETF - USD	+11.98%	0%	692,025 M€
VANGUARD GROWTH ETF PORTFOLIO - CAD	+10.88%	0%	7,793 M€
VANGUARD MORNINGSTAR U.S. TOTAL MARKET INDEX ETF - CAD	+14.14%	0%	14,144 M€
UPAR ULTRA RISK PARITY ETF - USD	+2.51%	0%	59 M€
ELM MARKET NAVIGATOR ETF - USD	+7.89%	0%	594 M€
VANGUARD CONSERVATIVE ETF PORTFOLIO - CAD	+3.98%	0%	688 M€
DEFINED DURATION 20 ETF - USD	+12.20%	0%	19 M€
RPAR RISK PARITY ETF - USD	+2.48%	0%	580 M€
VANGUARD CONSERVATIVE INCOME ETF PORTFOLIO - CAD	+0.63%	0%	184 M€
CI GLOBAL CORE PLUS EQUITY ETF - CAD	0.00%	0%	43 M€
VANGUARD RETIREMENT INCOME ETF PORTFOLIO - CAD	+1.53%	0%	267 M€
CLEARSHARES OCIO ETF - DISTRIBUTING - USD	+8.99%	0%	176 M€
CAMBRIA TAX AWARE ETF - USD	+6.68%	0%	26 M€
AB US EQUITY ETF - USD	+8.91%	0%	727 M€
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD	+15.08%	0%	12,086 M€
CAMBRIA US EW ETF - USD	+10.01%	0%	194 M€
DEFINED DURATION 5 ETF - USD	+0.74%	0%	18 M€
CAMBRIA GLOBAL EW ETF - USD	+8.26%	0%	146 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD	+10.77%	0%	513 M€
CAMBRIA ENDOWMENT STYLE ETF - USD	+12.56%	0%	156 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+13.52%	-.--%	62 M€

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

Employees

Sector

More about the company